Detalhe da pesquisa
1.
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538060
2.
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury.
Clin Chem Lab Med
; 62(2): 322-331, 2024 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37702323
3.
Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis.
Clin Proteomics
; 20(1): 33, 2023 Aug 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37644477
4.
A national case-control study investigating demographic and environmental factors associated with NMOSD.
Mult Scler
; 29(4-5): 521-529, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36803237
5.
Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
Mult Scler
; 29(6): 719-730, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012898
6.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37905526
7.
Complement Inhibition in Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder.
Can J Neurol Sci
; 50(2): 165-173, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34895385
8.
Serum neurofilament light in MS: The first true blood-based biomarker?
Mult Scler
; 28(10): 1491-1497, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33565908
9.
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Mult Scler
; 28(8): 1277-1285, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34994579
10.
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Mult Scler
; 28(5): 790-800, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34382875
11.
Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Eur J Neurol
; 29(7): 2024-2035, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274413
12.
Autologous hematopoietic stem cell transplantation for multiple sclerosis: A current perspective.
Mult Scler
; 27(2): 167-173, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32364422
13.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2021.
MMWR Morb Mortal Wkly Rep
; 70(6): 193-196, 2021 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33571173
14.
Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.
N Engl J Med
; 376(22): 2122-2133, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28564557
15.
Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment.
Mult Scler
; 26(5): 540-547, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31965903
16.
Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: Pooled analysis of clinical trials.
Mult Scler
; 26(9): 1083-1092, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31172849
17.
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
Mult Scler
; 26(13): 1719-1728, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31675266
18.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 26(13): 1729-1739, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31680631
19.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2020.
MMWR Morb Mortal Wkly Rep
; 69(5): 133-135, 2020 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32027627
20.
Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.
BMC Neurol
; 20(1): 364, 2020 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33023488